| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (NCT02559583) | Janssen-Cilag Ltd. | 2014-07-01 |
| Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization (NCT02184897) | Asan Medical Center | 2014-07-01 |
| A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib (NCT02115035) | University of Arkansas | 2014-07-01 |
| Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16) (NCT02917239) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2014-07-01 |
| STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS (NCT02215980) | Fondazione EMN Italy Onlus | 2014-07-01 |
| Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation (NCT05697913) | Hospital Galdakao-Usansolo | 2014-07-01 |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (NCT02155634) | Celgene | 2014-07-01 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer (NCT02184533) | Stanford University | 2014-07-01 |
| A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. (NCT02164955) | Celgene | 2014-06-26 |
| UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (NCT02128230) | University of Arkansas | 2014-06-10 |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NCT02103335) | Celgene | 2014-06-05 |
| Prevalence of Asymptomatic Thrombosis in Multiple Myeloma (NCT03145870) | Centre Hospitalier Universitaire, Amiens | 2014-06-03 |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (NCT02117115) | Washington University School of Medicine | 2014-06-01 |
| Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (NCT02204241) | European Myeloma Network B.V. | 2014-06-01 |
| Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma (NCT02315157) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-06-01 |
| Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (NCT02185820) | European Myeloma Network B.V. | 2014-06-01 |
| Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (NCT02148913) | Corewell Health West | 2014-06-01 |
| Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma (NCT02100657) | PharmaMar | 2014-06-01 |
| Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. (NCT03405571) | University of Athens | 2014-06-01 |
| Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (NCT01946477) | Celgene | 2014-05-29 |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma (NCT02057640) | Jason Valent | 2014-05-22 |
| CART-19 for Multiple Myeloma (NCT02135406) | University of Pennsylvania | 2014-05-01 |
| A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD) (NCT02244125) | Institut Curie | 2014-04-14 |
| A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT02116569) | Janssen Pharmaceutical K.K. | 2014-04-01 |
| Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma (NCT02056756) | Stichting European Myeloma Network | 2014-04-01 |
| Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy (NCT02093910) | Sun Yat-sen University | 2014-04-01 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (NCT02110563) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2014-04-01 |
| A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma (NCT02078102) | Sherif S. Farag | 2014-03-11 |
| Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients (NCT02159365) | Bristol-Myers Squibb | 2014-03-08 |
| Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma (NCT02046070) | Millennium Pharmaceuticals, Inc. | 2014-03-05 |
| Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02077959) | Ohio State University Comprehensive Cancer Center | 2014-03-03 |
| Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation (NCT02087657) | University of Kansas Medical Center | 2014-03-01 |
| Evaluation of Cardiotoxic Effects of Bortezomib (NCT02026505) | Oregon Health and Science University | 2014-03-01 |
| Vinorelbine and Gemcitabine in Myeloma (NCT02791373) | Insel Gruppe AG, University Hospital Bern | 2014-03-01 |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma (NCT01997840) | Celgene | 2014-03-01 |
| Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency (NCT02045017) | Celgene | 2014-02-28 |
| A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (NCT01998971) | Janssen Research & Development, LLC | 2014-02-18 |
| A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) (NCT02036502) | Merck Sharp & Dohme LLC | 2014-02-14 |
| Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT (NCT03963024) | IRCCS San Raffaele | 2014-02-12 |
| Non-interventional Study With Pomalidomide (Imnovid®) (NCT02075996) | iOMEDICO AG | 2014-02-11 |
| Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (NCT02405364) | University Hospital, Toulouse | 2014-02-01 |
| Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT (NCT03977103) | University Of Perugia | 2014-02-01 |
| CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (NCT01995708) | Memorial Sloan Kettering Cancer Center | 2014-01-31 |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma (NCT02043860) | University of Illinois at Chicago | 2014-01-10 |
| Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma (NCT02302495) | University Hospital, Lille | 2014-01-08 |
| Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma (NCT04558853) | Karolinska University Hospital | 2014-01-01 |
| MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis (NCT02270307) | National Research Center for Hematology, Russia | 2014-01-01 |
| Microdose Study of Melphalan, Bortezomib and Dexamethasone (NCT02109861) | Henrik Gregersen | 2014-01-01 |
| Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (NCT02773550) | Basque Health Service | 2014-01-01 |
| A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (NCT02072863) | Amgen | 2014-01-01 |
| Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. (NCT02452099) | Maria Sklodowska-Curie National Research Institute of Oncology | 2014-01-01 |
| A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR (NCT02387879) | Celgene | 2013-12-25 |
| IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE (NCT02023671) | Azienda Ospedaliera San Giovanni Battista | 2013-12-01 |
| Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma (NCT01962792) | Pharmacyclics LLC. | 2013-12-01 |
| Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma (NCT02011113) | Celgene Corporation | 2013-12-01 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692) | Merck Sharp & Dohme LLC | 2013-11-22 |
| Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers (NCT02129569) | Case Comprehensive Cancer Center | 2013-11-11 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma (NCT01937442) | Celgene | 2013-11-07 |
| Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma (NCT02002598) | Suzanne Lentzsch, MD | 2013-11-01 |
| Maintenance Therapy With Subcutaneous Bortezomib (NCT01913730) | European Myeloma Network B.V. | 2013-11-01 |
| Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) (NCT01947309) | Celgene | 2013-11-01 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (NCT01881789) | Amgen | 2013-10-28 |
| CT Antigen TCR-Engineered T Cells for Myeloma (NCT01892293) | Adaptimmune | 2013-10-15 |
| Meloxicam vs Placebo for Mobilization (NCT02003625) | Massachusetts General Hospital | 2013-10-01 |
| Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance (NCT01702831) | University Health Network, Toronto | 2013-10-01 |
| Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) (NCT01971658) | Nantes University Hospital | 2013-10-01 |
| Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients (NCT02035189) | University of Arkansas | 2013-10-01 |
| Oligosecretary Myeloma: Prevalence and Its Clinical Significance (NCT02095379) | Samsung Medical Center | 2013-10-01 |
| Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (NCT02248402) | Chonnam National University Hospital | 2013-10-01 |
| An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD (NCT01985126) | Janssen Research & Development, LLC | 2013-09-27 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (NCT01947140) | Jennifer Amengual | 2013-09-09 |
| Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old (NCT01916252) | PETHEMA Foundation | 2013-09-01 |
| Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors (NCT02078518) | National University Hospital, Singapore | 2013-09-01 |
| Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma (NCT01858558) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-09-01 |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (NCT01846429) | H. Lee Moffitt Cancer Center and Research Institute | 2013-09-01 |
| Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (NCT02376933) | University of Arizona | 2013-08-20 |
| Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) (NCT01720875) | University of Leeds | 2013-08-09 |
| Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma (NCT01969565) | Emory University | 2013-08-01 |
| Treatment Optimization in Patients With Untreated Multiple Myeloma (NCT02145598) | Dr. med. Lars-Olof Muegge | 2013-08-01 |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (NCT01980589) | Amgen | 2013-08-01 |
| Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. (NCT02086942) | Yongping Zhai | 2013-08-01 |
| Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (NCT01818752) | Amgen | 2013-07-08 |
| Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT01832727) | Amgen | 2013-07-02 |
| Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (NCT01720043) | University of Utah | 2013-07-01 |
| Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (NCT01610999) | Tufts Medical Center | 2013-07-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (NCT01908387) | Celgene Corporation | 2013-07-01 |
| Phase I Trial of VS-6766 Alone and in Combination With Everolimus (NCT02407509) | Royal Marsden NHS Foundation Trust | 2013-06-17 |
| PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (NCT01855698) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-06-01 |
| Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma (NCT02187731) | Odense University Hospital | 2013-06-01 |
| Acupuncture for Chemotherapy-induced Peripheral Neuropathy (NCT01892852) | Pusan National University Hospital | 2013-06-01 |
| An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells (NCT01753453) | Sanofi | 2013-06-01 |
| Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (NCT01886976) | Chinese PLA General Hospital | 2013-06-01 |
| 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma (NCT01859234) | University Medical Center Groningen | 2013-05-01 |
| A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma (NCT01868828) | Peking University People's Hospital | 2013-05-01 |
| A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT01711671) | Leap Therapeutics, Inc. | 2013-05-01 |